编号：2019-002 证券代码：300086 证券简称：康芝药业 康芝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------|-----------------------------------|--------------------|----------| | | | | | | 投资者关系活动 | □ 特定对象调研 | 分析师会议 | | | 类别 | □ 媒体采访 | 业绩说明会 | | | | □ 新闻发布会 | 路演活动 | | | | √现场参观 | | | | | √其他 （机构投资者集中调研） | | | | | | | | | 参与单位名称及 | 1. 广州广证恒生证券研究所有限公司 | 唐爱金 | | | 人员姓名 | 2. 新时代证券股份有限公司 | 谭国超 | | | | 3. 中科沃土基金管理有限公司 | 孟禄程 | | | 时间 | 2019 年 5 月 28 日 | | | | 地点 | 广州 | | | | 上市公司接待人 | 康芝药业股份有限公司 | 副总裁兼董事会秘书 | ...

编号：2018-002 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 新闻发布会 □路演活动 现场参观 其他 证券代码：300086 证券简称：康芝药业 康芝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------|----------------------------------------------------|----------------------------|--------| | 参与单位名称及 人员姓名 | 信达证券股份有限公司 | | 吴临平 | 李惜浣 | | 时间 | 2018 年 6 月 21 日 | | | | | 地点 | 海口 | | | | | 上市公司接待人 员姓名 | 康芝药业股份有限公司 康芝药业股份有限公司 康芝药业股份有限公司 | 副总裁兼董事会秘书 财务总部总经理 证券事务代表 | 林德新； ...

证券代码：300086 证券简称：康芝药业 康芝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------|--------------------------------------------------------------------| | | | | | | | 投资者关系活动 类别 | □ 特定对象调研 | 分析师会议 | | | | | □ 媒体采访 | 业绩说明会 | | | | | □ 新闻发布会 | 路演活动 | | | | | √现场参观 | | | | | | √其他 （机构投资者集中调研 ...

康芝药业股份有限公司 2022 年第三季度报告 证券代码：300086 证券简称：康芝药业 公告编号：2022-067 康芝药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1 康芝药业股份有限公司 2022 年第三季度报告 （二） 非经常性损益项目和金额 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 期增减 | | 年同期增减 | | 营业收入（元） | 120,037,715.53 | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥229,128,073.36, a decrease of 45.90% compared to ¥423,547,126.62 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was -¥87,769,940.90, representing a decline of 52.28% from -¥57,637,137.02 in the previous year[22]. - The basic earnings per share were -¥0.1950, a decrease of 52.22% from -¥0.1281 in the same period last year[22]. - The diluted earnings per share also stood at -¥0.1950, reflecting the same percentage decline as the basic earnings per share[22]. - The weighted average return on net assets was -6.01%, a decline of 2.10% compared to -3.91% in the previous year[22]. - The company's revenue for the reporting period was ¥229,128,073.36, a decrease of 45.90% compared to ¥423,547,126.62 in the same period last year, primarily due to the exclusion of Kangzhi Hospital from the consolidated financial statements and a decline in main business income[90]. - The company's operating costs were ¥125,442,701.97, down 49.35% from ¥247,666,481.13 in the previous year, reflecting the same reasons as the revenue decline[90]. - The gross profit margin for the pharmaceutical industry segment was 49.78%, down 18.23% year-on-year, while the gross profit margin for maternal and infant health products was 21.17%, down 28.56%[94]. Cash Flow and Investments - The net cash flow from operating activities improved to ¥4,132,029.41, a significant increase of 146.36% compared to -¥8,913,213.49 in the same period last year[22]. - The total cash and cash equivalents decreased by 74.76% to ¥-115,984,579.24, influenced by increased cash inflows from operating activities and reduced cash inflows from financing activities[92]. - The net cash flow from investment activities improved by 32.87%, amounting to ¥-42,212,197.65, due to reduced fixed asset purchases and financial product investments[92]. - The total amount of funds raised was ¥144,879.77 million, with ¥66.97 million invested during the reporting period[104]. - The company has received a total of 5.5 million RMB in government subsidies for three projects, including the consistency evaluation of montmorillonite powder generic drugs and the introduction of new products like aminophenol granules[61]. Product Development and Market Position - The company operates 16 subsidiaries, including 12 first-level and 4 second-level subsidiaries, focusing on children's health products and medical protective equipment[30]. - The company has over 30 children's drug products, including the best-selling antipyretic and analgesic series, cold series, and antimicrobial series[31]. - The company has established a comprehensive product structure in the pediatric medication field, covering categories such as anti-infection, respiratory, digestive, neurological, anti-allergy, and nutritional supplements[54]. - The pediatric drug market in China is experiencing strong demand, supported by regulatory initiatives encouraging the development of pediatric medications[52]. - The company has developed over 30 pediatric drug varieties, covering common pediatric diseases such as fever, cough, vomiting, and diarrhea[71]. Regulatory Compliance and Certifications - The company has received EU certification for its medical protective masks and has production capabilities for hand sanitizers[31]. - The company holds multiple GMP certificates for various pharmaceutical products, with the latest valid until February 2024 and June 2022 for different product categories[80][81]. - The medical device production license is valid until August 2025, covering II class medical devices including surgical infection control products[80]. - The company is focused on compliance with regulatory standards to enhance its operational capabilities and market competitiveness[84]. Strategic Initiatives and Future Plans - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[5]. - The company continues to focus on "new products, new customers, new channels, and new strategies" as key drivers for performance growth[48]. - The company is positioned in a growing pharmaceutical industry, with significant opportunities arising from increasing health awareness and government support for healthcare development[50]. - The company plans to enhance production capacity and market promotion for its children's medicine product line, which has not yet met expected returns[110]. - The company is actively pursuing new product development and market expansion strategies to recover from the revenue decline[90]. Environmental and Social Responsibility - 康芝药业在2022年上半年积极参与社会公益，捐赠防疫物资以支持疫情防控工作[167]. - 康芝药业的海南基地和河北康芝均设有污水处理站，污水处理设施运行正常，未出现超标排放情况[158]. - 河北康芝的锅炉废气每年委托有资质单位进行检测，未发生过超标情况[158]. - 康芝药业通过光伏新能源发电项目和工艺技术更新等措施，积极推行节能减排工作[164]. - 康芝药业在2021年被评为环保诚信企业，属于环保信用评价的最高级别[165]. Shareholder Commitments and Governance - The actual controller of the company, Hong Jiangyou, committed to not transferring or entrusting others to manage shares for 36 months post-IPO[172]. - The High-tech Zone Group guaranteed not to reduce its 10% stake in the company for 24 months following the share transfer[172]. - The company has not engaged in any business that competes with its subsidiaries, ensuring no conflict of interest[174]. - The commitments made by shareholders are aimed at ensuring the long-term stability and growth of the company[172]. - The company has not reported any overdue commitments as of the end of the reporting period[172]. Risks and Challenges - The company faces intensified competition in the pediatric medicine market, with potential risks from increased capital entering the industry due to favorable national policies[129]. - Regulatory changes in the pharmaceutical industry, including cost control measures and procurement policies, pose risks to the company's profitability[130]. - Environmental protection regulations may increase operational costs, prompting the company to invest in environmental management systems[132]. - Currency fluctuations could impact the company's import and export pricing, necessitating effective foreign exchange risk management strategies[133].

Financial Performance - The company's operating revenue for Q1 2022 was ¥109,945,844.25, a decrease of 40.90% compared to ¥186,023,819.29 in the same period last year[3] - The net profit attributable to shareholders was -¥46,239,789.41, representing a decline of 54.76% from -¥29,878,131.01 year-on-year[3] - Basic earnings per share decreased by 54.82% to -¥0.1028 from -¥0.0664 in the same period last year[5] - Net profit for Q1 2022 was a loss of ¥47,321,037.01, compared to a loss of ¥30,020,660.14 in Q1 2021, representing a 57% increase in losses[28] Cash Flow - The net cash flow from operating activities was -¥43,702,923.47, a significant decrease of 363.74% compared to ¥16,570,263.12 in the previous year[3] - Cash inflow from operating activities totaled ¥143,161,131.71, down from ¥236,867,174.81 in the previous year[32] - Investment activities resulted in a net cash outflow of -¥35,299,406.40, compared to -¥29,321,654.95 in Q1 2021[32] - In Q1 2022, the net cash flow from financing activities was -20,136,535.58 CNY, compared to -31,079,524.45 CNY in the same period last year[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,359,300,615.33, down 4.05% from ¥2,458,781,654.13 at the end of the previous year[5] - The equity attributable to shareholders decreased by 3.07% to ¥1,457,709,429.86 from ¥1,503,949,219.27 at the end of the previous year[5] - Total liabilities decreased to ¥1,077,300,777.63 from ¥1,128,437,643.13, a decline of 4.5%[24] - The total liabilities decreased to ¥852,979,787.56 from ¥905,139,789.35, reflecting a reduction of approximately 5.8%[28] Operational Changes - The company attributed the revenue decline to a reduction in the number of consolidated entities following the sale of its medical service business in July 2021[8] - Increased marketing expenses contributed to the significant drop in net profit and cash flow from operating activities[8] - Research and development expenses for Q1 2022 were ¥4,262,780.66, down 24% from ¥5,600,126.59 in Q1 2021[27] Government Support and Community Engagement - The company received government subsidies amounting to ¥3,882,005.61 during the reporting period[7] - The company actively participated in pandemic relief efforts by donating children's masks to support COVID-19 prevention in Hong Kong[19] Market Development - The company is pursuing further development in the European market, following a visit from Belgian officials expressing interest in collaboration[18] - The company has five drug research and development projects in the registration process, with three new drug projects currently undergoing clinical research[18] Training and Awareness - The company hosted an online training conference for nearly 1,000 participants, focusing on women's health and menopause awareness[18] Audit Status - The company did not conduct an audit for the Q1 2022 report[34]

Financial Performance - The total revenue for 2021 was ¥836,565,805.56, a decrease of 9.23% compared to ¥921,642,902.81 in 2020[24]. - The net profit attributable to shareholders was ¥10,987,504.99, an increase of 17.65% from ¥9,339,252.11 in 2020[24]. - The net cash flow from operating activities improved to ¥11,329,336.82, a significant increase of 167.67% compared to -¥16,742,829.71 in 2020[24]. - The basic earnings per share rose to ¥0.0244, reflecting a growth of 17.31% from ¥0.0208 in 2020[24]. - The total operating revenue for 2021 was CNY 836,565,805.56, a decrease from CNY 921,642,902.81 in 2020[25]. - Revenue from the pharmaceutical industry increased by 4.90% to ¥573,806,985.07, accounting for 68.59% of total revenue[86]. - Revenue from maternal and infant health products decreased by 9.73% to ¥99,449,581.24, maintaining an 11.89% share of total revenue[86]. - Revenue from medical services saw a significant decline of 38.25%, totaling ¥163,309,239.25, which accounted for 19.52% of total revenue[86]. - Children's medicine revenue reached ¥309,585,821.97, a 29.25% increase year-over-year[89]. - Adult medicine revenue was ¥228,707,476.34, reflecting a 2.04% increase year-over-year[89]. - Medical device revenue significantly decreased to ¥6,178,482.98, down 89.10% year-over-year[89]. - Medical services revenue dropped to ¥163,190,339.76, a decrease of 38.22% year-over-year[89]. - Domestic revenue accounted for 99.92% of total revenue, totaling ¥835,937,755.18, down 8.96% year-over-year[89]. - Direct sales contributed ¥732,911,023.20, representing 87.61% of total sales, a decrease of 12.86% year-over-year[89]. - The gross profit margin for the pharmaceutical industry was 57.46%, an increase of 0.88% year-over-year[91]. - R&D expenses were ¥14,704,659.61, a decrease of 11.27% compared to the previous year[104]. - The number of R&D personnel decreased to 110 in 2021, a decline of 72.77% compared to 404 in 2020[106]. - R&D investment amounted to ¥20,782,367.88 in 2021, representing 2.48% of operating revenue, up from 2.11% in 2020[107]. - The cash and cash equivalents decreased by 107.94% to -¥7,253,412.14, mainly due to loan repayments and the exclusion of cash flows from the medical services segment[110]. - The company reported a net profit of -420,183.07 million yuan from its subsidiary Hainan Kangzhi Biological, indicating a significant loss in the pharmaceutical sales sector[138]. - The overall net profit contribution from major subsidiaries is critical, with those exceeding 10% impact on the company's net profit being closely monitored[139]. Market Position and Strategy - The company aims to leverage the opportunities presented by the "three-child" policy to expand its market presence in pediatric pharmaceuticals[37]. - The pediatric drug market is expected to grow due to supportive government policies and increasing demand for specialized medications[36]. - The company is focusing on the pediatric medication market, which is anticipated to expand due to government policies promoting the development of children's drugs[143]. - The company is strategically positioned to leverage the growing demand for pediatric medications, supported by favorable regulatory changes and increased societal awareness[143]. - The company aims to become a leading brand in China's children's health industry through strategic resource allocation and innovative marketing strategies[57]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position, although specific targets were not mentioned[174]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[183]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's production capacity by 25%[183]. Research and Development - The company has a strong focus on R&D, holding over 40 national invention and utility model patents in the mother and baby health sector[38]. - The company has developed advanced technology platforms for children's medication, including oral fast-dissolving films and drug micro-particle preparation[55]. - The company plans to enrich its product line with new drugs, including Ibuprofen Deoxycorticosterone Tablets and Children's Dextromethorphan Hydrobromide Membrane, currently in clinical research[106]. - The company is focusing on enhancing its new drug research and development, particularly in areas such as hand-foot-mouth disease and broad-spectrum antiviral drugs[148]. - The company has initiated clinical research for Suramin sodium's potential in treating kidney diseases, expanding its therapeutic applications[56]. - The company has completed Phase I clinical trials for its injectable Suramin sodium, aimed at treating hand-foot-mouth disease, and has received clinical trial approval for a new indication related to acute kidney injury[56]. Corporate Governance and Management - The company has established a robust corporate governance structure to protect shareholder rights and ensure compliance with relevant regulations[159]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements[161]. - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with investors[163]. - The company reported no significant differences between its governance practices and the regulations set by the China Securities Regulatory Commission[165]. - The company has a clear decision-making process for determining remuneration based on profitability and individual performance[191]. - The board of directors held multiple meetings throughout 2021, with significant resolutions announced on April 2, April 22, and June 7[194]. - The company maintained compliance with the Shenzhen Stock Exchange regulations throughout the reporting period[198]. - The company has a diverse board with independent directors contributing to governance[192]. Risks and Challenges - The company faces risks from intensified industry competition and regulatory changes, which may impact its market position and profitability[149]. - The average profit margin in the pharmaceutical industry is declining due to ongoing healthcare reforms and pricing controls, posing a risk to the company's financial performance[150]. - The ongoing COVID-19 pandemic poses risks to production operations, with potential impacts on marketing activities and rising costs for materials, labor, and logistics[153]. - The company is cautious about the marketing network project due to rapid changes in the industry and regulatory environment[125]. - There is a risk of goodwill impairment due to fluctuations in the operating conditions of acquired companies, which could negatively impact the company's financial results[152]. Product Development and Innovation - The company has developed a comprehensive product chain in maternal and infant health products, including over 40 patents in this sector[59]. - The company has established a comprehensive product portfolio in pediatric medicine, including categories such as anti-infection and respiratory treatments[37]. - The company is actively involved in setting industry standards for infant laundry products, promoting safety and quality in the sector[48]. - The company launched a new product, a one-time hand sanitizer gel, and has been promoting it as part of its new product development plan[76]. - The company has completed the planning for the amino acid series new products and is advancing the development and promotion of various series of products[76]. Financial Management - The total remuneration paid to directors, supervisors, and senior management in 2021 amounted to 3.3084 million yuan[191]. - The highest remuneration among the directors was received by the chairman, who earned 460,000 yuan[192]. - The average remuneration for the directors, supervisors, and senior management is approximately 236,000 yuan per person[191]. - The financial director's remuneration was reported at 310,300 yuan[193]. - The company emphasizes performance-based remuneration for its management team[191]. - The company has a valid drug production license until October 15, 2025, covering a range of products including powder injections and capsules[65]. - The company has obtained GMP certification for its production facilities, ensuring compliance with quality management standards until June 25, 2022[66].

Financial Performance - The company's operating revenue for Q3 2021 was ¥162,595,384.46, a decrease of 26.29% compared to the same period last year[3]. - The net profit attributable to shareholders increased by 401.55% to ¥16,031,623.47, while the net profit after deducting non-recurring gains and losses was a loss of ¥27,635,605.09, a decrease of 1,158.97%[3][6]. - Basic and diluted earnings per share were both ¥0.0356, reflecting a significant increase of 401.91% compared to the previous year[3]. - Total operating revenue for Q3 2021 was ¥586,142,511.08, a decrease of 7.2% compared to ¥631,912,612.28 in the same period last year[24]. - Net profit for Q3 2021 was a loss of ¥41,118,374.68, compared to a profit of ¥7,167,994.16 in Q3 2020, marking a significant decline[25]. - Operating profit for the period was a loss of ¥31,997,634.02, compared to a profit of ¥18,908,292.39 in the same quarter last year[25]. - Basic and diluted earnings per share were both -¥0.0925, a decline from ¥0.0047 in the same quarter last year[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,396,849,400.90, down 8.30% from the end of the previous year[3]. - The total liabilities decreased to CNY 895,712,377.30 from CNY 1,011,926,437.60, representing a reduction of approximately 11.5%[22]. - The total equity attributable to the parent company decreased to CNY 1,451,854,548.88 from CNY 1,502,456,900.61, a decline of approximately 3.4%[22]. - The company's current assets totaled CNY 712,128,575.36, slightly up from CNY 708,975,279.40 at the end of 2020, indicating a marginal increase of about 0.2%[21]. - Cash and cash equivalents increased to CNY 305,885,541.51 from CNY 258,269,712.13, marking a growth of about 18.4%[19]. - The company reported a significant reduction in accounts receivable, which fell to CNY 67,525,455.22 from CNY 145,673,131.84, a decrease of approximately 53.7%[19]. - Inventory levels rose to CNY 218,262,347.75 from CNY 209,952,716.46, reflecting an increase of about 3.1%[21]. Non-Recurring Items - Non-recurring gains and losses for the reporting period totaled ¥43,667,228.56, primarily from non-current asset disposal gains[4]. - The company reported a significant decrease in net profit due to a reduction in the number of consolidated entities and increased marketing expenses[6]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,090[8]. - The largest shareholder, Hainan Hongshi Investment Co., Ltd., held 29.49% of the shares, amounting to 132,695,947 shares[8]. - The total equity attributable to shareholders decreased by 3.37% to ¥1,451,854,548.88 compared to the end of the previous year[3]. Corporate Developments - The company announced the initiation of Phase II clinical trials for a new indication of sodium sulfanilate for acute kidney injury, receiving implied approval from the National Medical Products Administration[12]. - The company completed the sale of 100% equity in Guangdong Kangzhi Hospital Management Co., Ltd., and the associated hospitals will no longer be included in the consolidated financial statements[13]. - The company appointed Cheng Pengfei as the new Chief Financial Officer following the resignation of the previous CFO, effective September 30, 2021[12]. - The company approved the use of up to 75 million RMB of temporarily idle raised funds for cash management, ensuring that investment and acquisition activities remain unaffected[15]. - The first employee stock ownership plan holds a total of 2,372,586 shares, with some shares transferred to individual accounts during the reporting period[14]. Research and Development - Research and development expenses increased to ¥14,844,817.36, up from ¥12,611,713.79, reflecting a focus on innovation[24]. Community Engagement - Kangzhi Pharmaceutical was recognized for its contributions to the Hainan economy and awarded the "Hainan Province Contribution Award" during a recent ceremony[18]. - The company actively participated in disaster relief efforts in Henan province, providing essential supplies in response to extreme weather events[18]. Financial Reporting - The third quarter report for 2021 was not audited, indicating a potential area of concern for investors[36]. - The company has adopted new leasing standards starting from 2021, which required adjustments to the financial statements[36]. - The company has not disclosed any new product developments or market expansion strategies in the current report[37].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥423,547,126.62, representing a 2.97% increase compared to ¥411,318,235.60 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was -¥57,637,137.02, a decrease of 873.60% from ¥7,450,481.94 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥59,384,735.43, a decline of 2,050.60% compared to ¥3,044,435.41 in the same period last year[25]. - The net cash flow from operating activities was -¥8,913,213.49, showing a 92.76% improvement from -¥123,080,835.57 in the previous year[25]. - The total assets at the end of the reporting period were ¥2,580,383,376.68, a decrease of 1.27% from ¥2,613,674,492.96 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company were ¥1,435,819,763.59, down 4.44% from ¥1,502,456,900.61 at the end of the previous year[25]. - The basic earnings per share were -¥0.1281, a decline of 871.69% from ¥0.0166 in the previous year[25]. - The diluted earnings per share were also -¥0.1281, reflecting the same percentage decline as the basic earnings per share[25]. - The weighted average return on net assets was -3.91%, a decrease of 4.41% compared to 0.50% in the previous year[25]. - The company reported a significant decrease in financing cash flow, down 97.30% to ¥5,425,873.31 from ¥201,211,471.85 in the previous year, primarily due to reduced loans[99]. - The net increase in cash and cash equivalents was -¥66,369,145.41, a decline of 440.37% from an increase of ¥19,499,388.41 in the same period last year[99]. Business Operations - The company operates 24 subsidiaries, including 13 first-level subsidiaries, focusing on children's health products and medical services[32]. - The company has over 30 children's medications, including the best-selling antipyretic and analgesic series, and has production bases in Hainan, Northeast, North China, and Guangdong[33]. - The company is constructing a new production base in Zhongshan, Guangdong, compliant with EU standards, to enhance its production capacity[33]. - The company has received various government honors for its hospital operations, including being recognized as a model hospital in Yunnan Province[37]. - The company has a diverse product range, including medical masks and disinfectants, with certifications for EU compliance[33]. - The company has expanded into reproductive medicine and women's health services through acquisitions, holding 51% stakes in two hospitals[37]. - The company has advanced R&D capabilities and a strong team, contributing to its product development and innovation[33]. - The company has established a comprehensive sales strategy centered around a "New Kangzhi Model," focusing on high-quality products and cooperative partnerships[48]. - The company achieved stable growth across all business segments in the first half of 2021, without the severe fluctuations experienced in the same period last year due to the pandemic[50]. Research and Development - The company has established a comprehensive product portfolio in the pediatric medication sector, including categories such as anti-infection, respiratory, digestive, and allergy treatments[53]. - The company has successfully developed and launched new products, including amino acid series and probiotics series, with production orders already placed[59]. - The company received 80,000 RMB in research vouchers for its disposable medical masks and surgical masks, and 30.73 million RMB in industrial development special funds[59]. - The company is focusing on expanding its reproductive health services and integrating resources in suitable regions, particularly around Guangzhou and Hainan[58]. - The company is focused on the research and development of new drugs and technologies to strengthen its market position and expand its product offerings[73]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[97]. - A recent acquisition of a local competitor is expected to enhance production capacity by 30%[97]. - The company plans to enhance its digital marketing efforts, aiming for a 50% increase in online sales channels[95]. - The company is actively pursuing market expansion strategies to increase its footprint in the pharmaceutical sector[90]. Compliance and Regulatory - The company has obtained GMP certification for tablets and capsules, valid until February 20, 2024, and for powder injections, which expired on June 25, 2022[83]. - The company has a medical device production license valid until August 3, 2025, covering various medical supplies[83]. - The company has a disinfection product production license valid until December 30, 2023, for gel disinfectants[84]. - The company has established wastewater treatment stations at both its Hainan and Hebei facilities, ensuring that industrial wastewater is treated and meets standards before being discharged into municipal sewage systems[169]. - The company reported no instances of exceeding emission standards for wastewater, with a total wastewater discharge of 20.921 tons per year from Hainan and 16.526 tons per year from Hebei, both within regulatory limits[170]. - The company has received no administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[174]. Shareholder and Management - The controlling shareholder, Hong's Investment, transferred 45 million shares (10% of total shares) to High-tech Zone Group, with the transfer completed on July 4, 2019[179]. - High-tech Zone Group committed not to reduce its holdings of 10% shares in Kangzhi Pharmaceutical within 24 months after the transfer[179]. - The controlling shareholders promised not to transfer or manage their shares for 36 months post-IPO, ensuring stability in shareholding[179]. - The company has implemented an employee stock ownership plan, allowing up to 180 key employees to participate, with a funding ratio of 1:3 between self-raised funds and loans from the controlling shareholder[154]. - The employee stock ownership plan has resulted in the purchase of 2,675,000 shares at an average price of 22.58 RMB per share, representing 0.89% of the company's total share capital[155]. Risks and Challenges - The company faces risks from intensified industry competition and regulatory changes, which could impact future profitability[143]. - The average profit margin in the pharmaceutical industry is declining due to government policies, posing a risk to the company's pricing strategy[144]. - The company is exposed to foreign exchange risks as its import and export volumes increase, and it plans to strengthen its foreign exchange risk management strategies[146]. - The ongoing COVID-19 pandemic poses operational risks, and the company is adjusting its product structure and marketing strategies to mitigate short-term impacts on sales[147].

Financial Performance - The company's revenue for Q1 2021 was ¥186,023,819.29, representing a 9.28% increase compared to ¥170,227,713.62 in the same period last year[8]. - The net profit attributable to shareholders was -¥29,878,131.01, a decrease of 160.57% from -¥11,466,339.15 in the previous year[8]. - The basic earnings per share were -¥0.0664, a decline of 160.39% from -¥0.0255 in the same period last year[8]. - The weighted average return on equity was -2.01%, down from -0.77% in the previous year[8]. - Total profit decreased by 101.61% to -¥29,046,409.25 from -¥14,407,481.05, primarily due to increased period expenses[24]. - The operating profit was CNY -28,560,690.32, a decrease of 111.93% compared to the same period last year[28]. - Net profit for the first quarter was a loss of CNY 30,020,660.14, compared to a loss of CNY 14,455,278.79 in the previous year, representing a 107.5% increase in losses[75]. Cash Flow - The net cash flow from operating activities improved significantly to ¥16,570,263.12, compared to -¥125,758,512.07 in the same period last year, marking a 113.18% increase[8]. - Operating cash inflow increased by 31.28% to ¥236,867,174.81 from ¥180,432,802.68, attributed to increased sales revenue[24]. - Cash flow from operating activities net amount improved by 113.18% to ¥16,570,263.12 from -¥125,758,512.07, due to increased cash inflow and reduced cash outflow[24]. - Cash inflow from operating activities amounted to 236,867,174.81, compared to 180,432,802.68 in the prior period, reflecting a growth of approximately 31%[85]. - The net cash flow from investing activities was -29,321,654.95, an improvement from -52,168,815.61 in the previous period[87]. - Cash inflow from investing activities totaled 167,288,575.53, up from 88,419,146.76, representing an increase of approximately 89%[87]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,556,480,462.53, down 2.19% from ¥2,613,674,492.96 at the end of the previous year[8]. - The total liabilities decreased from ¥1,011,926,437.60 to ¥984,753,067.31, a reduction of approximately 2.8%[63]. - Current liabilities totaled ¥493,717,074.84, down from ¥580,776,254.77, representing a decrease of 15%[63]. - The company's total equity decreased from ¥1,601,748,055.36 to ¥1,571,727,395.22, a decline of 1.9%[65]. - The cash and cash equivalents decreased significantly from ¥158,487,632.41 to ¥62,055,742.63, a drop of 60.8%[64]. Shareholder Information - The top shareholder, Hainan Hongshi Investment Co., Ltd., holds 29.49% of the shares, totaling 132,695,947 shares[12]. - The total number of ordinary shareholders at the end of the reporting period was 29,285[12]. Government Subsidies - The company received government subsidies amounting to ¥1,241,613.06 during the reporting period[9]. - The company received government subsidies amounting to ¥1,241,613.06, an increase of 173.24% from ¥454,403.19[22]. Market and Product Development - The company continues to focus on children's health and premium strategies, emphasizing the development and sales of children's medicine and related healthcare products[28]. - The company faces risks from intensified industry competition and regulatory changes, which may impact future profitability[29]. - Average profit margins in the pharmaceutical industry are declining due to ongoing healthcare reforms and pricing controls[30]. - The company plans to enhance its new product development mechanisms and strengthen collaborations with research institutions to mitigate risks associated with new product launches[31]. Investment and Fundraising - Total fundraising amount reached CNY 144,879.77 million, with CNY 117.65 million invested in the current quarter[39]. - Cumulative investment of raised funds amounted to CNY 162,700.18 million, with no changes in usage reported[39]. - The construction of the children's drug production base project has been fully completed, achieving 100% of the planned investment of CNY 24,525 million[39]. - The company approved the use of up to CNY 75 million of idle raised funds for cash management, ensuring ongoing investment and acquisition activities are not affected[34]. Research and Development - Research and development expenses were CNY 5,600,126.59, slightly down from CNY 5,622,290.71 year-on-year[75]. - The company is focusing on the development of a new drug technology project for "Cefoperazone and Tazobactam Sodium Injection (3:1)"[41]. Acquisitions and Projects - The company has acquired 100% equity in Zhongshan Aihu Daily Necessities Co., Ltd. for 24,558 million[41]. - The company has completed the acquisition of 100% equity in Yuanning Pharmaceutical for RMB 38.41 million and has also allocated RMB 10 million for capital increase[47]. - The company has completed the acquisition of 100% equity in Zhongshan Hongshi Health Technology Co., Ltd. for RMB 30.1336 million, with an additional investment of RMB 49.8664 million planned for the construction of the Zhongshan Hongshi project[51]. Miscellaneous - The company received the "Love Unit Award" from the Hainan Charity Federation for its contributions during the COVID-19 pandemic[33]. - The company's product Montmorillonite Powder (3g) successfully passed the consistency evaluation for generic drugs, indicating equivalent quality and efficacy to the original product[33].